missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human Kallikrein 4 (aa 131-187) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Unit Size:
100µL
Description
Highest antigen sequence indentity to the following orthologs: Mouse (68%), Rat (68%). This recombinant protein control fragment may be used for blocking experiments with the corresponding antibody, PA5-111343 (PA5-111343. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. A novel Kallikrein gene Prostase/KLK-L1 (also known as KLK4) is expressed and is up-regulated by androgens and progestins. KLK-L1 may be involved in the pathogenesis and/or progression of prostate, breast, and possibly other malignancies.
Specifications
Specifications
| Accession Number | Q9Y5K2 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 9622 |
| Name | Human Kallikrein 4 (aa 131-187) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | AI2A1; androgen-regulated message 1; ARM1; EMSP; Emsp1; enamel matrix serine protease 1; Enamel matrix serine proteinase 1; ESMP1; kallikrein; kallikrein 4 (prostase, enamel matrix, prostate); kallikrein related peptidase 4; kallikrein related-peptidase 4 (prostase, enamel matrix, prostate); kallikrein-4; Kallikrein-like protein 1; kallikrein-related peptidase 4; Klk4; KLK-4; KLKL1; KLK-L1; Prostase; protease, serine 17 (enamel matrix, prostate); Prss17; PSTS; serine protease 17 |
| Common Name | Kallikrein 4 |
| Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction